News by Subject Medicine & Health

The researchers have discovered that USP7 inhibitors -under development by several pharmaceutical companies for the treatment of cancer- trigger a premature activation of cell cycle proteins, leading to uncontrolled cancer cell division and death. * The paper rejects the premise that the therapeutic efficacy of these inhibitors is due to their effects on activating the tumor suppressor protein P53, as currently accepted by the international scientific community. These results extend the potential use of USP7 inhibitors to a wider range of patients.

Oblique Therapeutics AB, a Sweden-based biotech company, in collaboration with Karolinska Institutet (Stockholm, Sweden), Gothenburg University (Sweden) and several local biotechs published promising research results in the highly-acclaimed scientific journal Science Advances (AAAS) entitled: Rational Antibody design for Undruggable Targets using Kinetically Controlled Biomolecular probes.

Researchers have discovered a new way to transform the tissues surrounding prostate tumors to help the body's immune cells fight the cancer. The discovery, made in human and mouse cells and in laboratory mice, could lead to improvements in immunotherapy treatments for prostate cancer, the second most common cancer in men in the US.

Despite guidelines recommending de-escalation of treatment among older women with early breast cancer, many continue to be over treated.

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

Triple-negative breast cancer is an aggressive type of breast cancer with a high fatality rate. Currently, chemotherapy is the major treatment option, but the clinical result is unsatisfactory. A research team led by biologists at City University of Hong Kong (CityU) has identified and characterised a set of specific super-enhancers that stimulate the activity of the related critical cancer genes. The latest findings may help discover new effective drug targets for TNBC patients to improve their survival chance.

McMaster University researchers Ali Ashkar and Sophie Poznanski have uncovered that changing the metabolism of natural killer (NK) immune cells allows these cells to overcome the hostile conditions found inside tumours and destroy advanced ovarian and lung cancer.